Concepts (157)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hidradenitis Suppurativa | 4 | 2020 | 9 | 2.420 |
Why?
|
| Methotrexate | 2 | 2020 | 70 | 1.230 |
Why?
|
| Dermatologic Agents | 2 | 2020 | 233 | 0.960 |
Why?
|
| Skin Neoplasms | 7 | 2007 | 220 | 0.780 |
Why?
|
| Severity of Illness Index | 4 | 2020 | 853 | 0.780 |
Why?
|
| Lichen Planus | 2 | 2020 | 10 | 0.760 |
Why?
|
| Lichen Sclerosus et Atrophicus | 1 | 2020 | 10 | 0.640 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2019 | 99 | 0.630 |
Why?
|
| Vulvar Diseases | 1 | 2020 | 5 | 0.630 |
Why?
|
| Fibromyalgia | 1 | 2020 | 12 | 0.630 |
Why?
|
| Crohn Disease | 1 | 2019 | 31 | 0.600 |
Why?
|
| Quality of Life | 2 | 2019 | 964 | 0.600 |
Why?
|
| Pemphigoid Gestationis | 1 | 2018 | 3 | 0.560 |
Why?
|
| Pruritus Vulvae | 1 | 2018 | 1 | 0.560 |
Why?
|
| Vulvitis | 1 | 2018 | 1 | 0.560 |
Why?
|
| Adult | 12 | 2020 | 9256 | 0.460 |
Why?
|
| Female | 20 | 2020 | 19942 | 0.450 |
Why?
|
| Humans | 28 | 2020 | 32274 | 0.440 |
Why?
|
| Opportunistic Infections | 2 | 2002 | 19 | 0.380 |
Why?
|
| Melanosis | 1 | 2009 | 14 | 0.290 |
Why?
|
| Dermatitis, Atopic | 2 | 2018 | 103 | 0.290 |
Why?
|
| Dermis | 3 | 2002 | 17 | 0.290 |
Why?
|
| Retrospective Studies | 4 | 2020 | 3624 | 0.280 |
Why?
|
| Cryoglobulinemia | 1 | 2008 | 6 | 0.280 |
Why?
|
| Skin Ulcer | 1 | 2008 | 12 | 0.270 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2008 | 12 | 0.270 |
Why?
|
| Eosinophilia | 1 | 2007 | 11 | 0.260 |
Why?
|
| Cellulitis | 1 | 2007 | 12 | 0.260 |
Why?
|
| Transients and Migrants | 1 | 2009 | 197 | 0.250 |
Why?
|
| Middle Aged | 10 | 2020 | 11848 | 0.230 |
Why?
|
| Diagnosis, Differential | 6 | 2008 | 502 | 0.230 |
Why?
|
| Male | 10 | 2020 | 19437 | 0.210 |
Why?
|
| Neurodermatitis | 2 | 2018 | 3 | 0.210 |
Why?
|
| Hispanic Americans | 1 | 2009 | 772 | 0.210 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 292 | 0.200 |
Why?
|
| Actinomycetales | 1 | 2002 | 2 | 0.190 |
Why?
|
| Angiomatosis | 1 | 2002 | 2 | 0.190 |
Why?
|
| Lip Neoplasms | 1 | 2002 | 2 | 0.190 |
Why?
|
| Syphilis, Cutaneous | 1 | 2002 | 2 | 0.190 |
Why?
|
| Skin Diseases, Papulosquamous | 1 | 2002 | 2 | 0.190 |
Why?
|
| Leukemia, Lymphoid | 1 | 2002 | 4 | 0.190 |
Why?
|
| Fusarium | 1 | 2002 | 2 | 0.190 |
Why?
|
| Fibrosarcoma | 1 | 2002 | 3 | 0.190 |
Why?
|
| Corynebacterium Infections | 1 | 2002 | 3 | 0.190 |
Why?
|
| Lymphangioma | 1 | 2002 | 7 | 0.190 |
Why?
|
| Dermatomycoses | 1 | 2002 | 7 | 0.190 |
Why?
|
| Panniculitis, Lupus Erythematosus | 1 | 2002 | 6 | 0.190 |
Why?
|
| Nevus, Epithelioid and Spindle Cell | 1 | 2002 | 4 | 0.190 |
Why?
|
| Nevus, Pigmented | 1 | 2002 | 6 | 0.190 |
Why?
|
| Granuloma | 1 | 2002 | 14 | 0.190 |
Why?
|
| Sarcoma, Kaposi | 1 | 2002 | 9 | 0.190 |
Why?
|
| Mycosis Fungoides | 1 | 2002 | 12 | 0.190 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2002 | 13 | 0.190 |
Why?
|
| Prevalence | 2 | 2020 | 955 | 0.190 |
Why?
|
| Scalp | 1 | 2002 | 35 | 0.190 |
Why?
|
| Adenoma | 1 | 2002 | 34 | 0.190 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2002 | 42 | 0.190 |
Why?
|
| Head and Neck Neoplasms | 1 | 2002 | 137 | 0.170 |
Why?
|
| Skin Diseases | 1 | 2002 | 135 | 0.170 |
Why?
|
| Aged | 6 | 2020 | 10260 | 0.160 |
Why?
|
| Genitalia | 1 | 2020 | 9 | 0.160 |
Why?
|
| Melanoma | 3 | 2007 | 166 | 0.150 |
Why?
|
| Observer Variation | 1 | 2019 | 96 | 0.150 |
Why?
|
| Health Surveys | 1 | 2019 | 175 | 0.140 |
Why?
|
| Vulvar Lichen Sclerosus | 1 | 2018 | 1 | 0.140 |
Why?
|
| Vulvar Neoplasms | 1 | 2018 | 6 | 0.140 |
Why?
|
| Dermatitis, Contact | 1 | 2018 | 8 | 0.140 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 3898 | 0.140 |
Why?
|
| Photochemotherapy | 1 | 2018 | 14 | 0.140 |
Why?
|
| Young Adult | 2 | 2018 | 2648 | 0.130 |
Why?
|
| Case-Control Studies | 1 | 2019 | 854 | 0.130 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 757 | 0.120 |
Why?
|
| Postmenopause | 1 | 2018 | 424 | 0.120 |
Why?
|
| Pregnancy | 1 | 2018 | 961 | 0.110 |
Why?
|
| Neurilemmoma | 2 | 2005 | 17 | 0.100 |
Why?
|
| Skin | 2 | 2008 | 212 | 0.100 |
Why?
|
| Psoriasis | 1 | 2018 | 355 | 0.100 |
Why?
|
| Immunocompromised Host | 2 | 2002 | 53 | 0.090 |
Why?
|
| Treatment Outcome | 1 | 2020 | 3416 | 0.090 |
Why?
|
| Adolescent | 4 | 2009 | 3517 | 0.090 |
Why?
|
| Mastocytosis, Cutaneous | 1 | 2008 | 3 | 0.070 |
Why?
|
| Probability | 1 | 2009 | 155 | 0.070 |
Why?
|
| Age Distribution | 1 | 2009 | 194 | 0.070 |
Why?
|
| Amyloidosis | 1 | 2008 | 17 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2009 | 471 | 0.070 |
Why?
|
| Cetirizine | 1 | 2007 | 1 | 0.070 |
Why?
|
| Anti-Allergic Agents | 1 | 2007 | 6 | 0.070 |
Why?
|
| Blister | 1 | 2007 | 7 | 0.070 |
Why?
|
| Prednisone | 1 | 2007 | 69 | 0.060 |
Why?
|
| Pruritus | 1 | 2007 | 46 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2007 | 200 | 0.060 |
Why?
|
| Longitudinal Studies | 1 | 2009 | 757 | 0.060 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2007 | 71 | 0.060 |
Why?
|
| Recurrence | 1 | 2007 | 285 | 0.060 |
Why?
|
| Lymph Nodes | 1 | 2007 | 113 | 0.060 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2005 | 32 | 0.060 |
Why?
|
| North Carolina | 1 | 2009 | 1300 | 0.060 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2005 | 44 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2005 | 179 | 0.050 |
Why?
|
| Leiomyoma | 1 | 2004 | 15 | 0.050 |
Why?
|
| Cross-Sectional Studies | 1 | 2009 | 1479 | 0.050 |
Why?
|
| Uterine Neoplasms | 1 | 2004 | 26 | 0.050 |
Why?
|
| Infant | 2 | 2008 | 1010 | 0.050 |
Why?
|
| Parakeratosis | 1 | 2003 | 3 | 0.050 |
Why?
|
| Axilla | 1 | 2003 | 17 | 0.050 |
Why?
|
| Leprosy | 1 | 2002 | 2 | 0.050 |
Why?
|
| Neurofibroma | 1 | 2002 | 2 | 0.050 |
Why?
|
| Nevus, Blue | 1 | 2002 | 3 | 0.050 |
Why?
|
| Leishmaniasis | 1 | 2002 | 3 | 0.050 |
Why?
|
| Antibodies, Anticardiolipin | 1 | 2002 | 5 | 0.050 |
Why?
|
| Germinal Center | 1 | 2002 | 5 | 0.050 |
Why?
|
| Giant Cells | 1 | 2002 | 4 | 0.050 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 2002 | 6 | 0.050 |
Why?
|
| Clone Cells | 1 | 2002 | 35 | 0.050 |
Why?
|
| Salivary Glands, Minor | 1 | 2002 | 10 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2005 | 603 | 0.050 |
Why?
|
| Mycoses | 1 | 2002 | 20 | 0.050 |
Why?
|
| Sarcoidosis | 1 | 2002 | 33 | 0.050 |
Why?
|
| HIV-1 | 1 | 2002 | 46 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2002 | 55 | 0.050 |
Why?
|
| Breast | 1 | 2002 | 63 | 0.050 |
Why?
|
| Upper Extremity | 1 | 2002 | 68 | 0.050 |
Why?
|
| Cholesterol | 1 | 2002 | 262 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2005 | 543 | 0.030 |
Why?
|
| Silver Sulfadiazine | 1 | 2008 | 4 | 0.020 |
Why?
|
| Mast Cells | 1 | 2008 | 13 | 0.020 |
Why?
|
| Fluocinonide | 1 | 2008 | 11 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2008 | 24 | 0.020 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2008 | 19 | 0.020 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2008 | 7 | 0.020 |
Why?
|
| Epidermis | 1 | 2008 | 29 | 0.020 |
Why?
|
| Nerve Fibers | 1 | 2008 | 38 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2008 | 146 | 0.020 |
Why?
|
| Frozen Sections | 1 | 2007 | 19 | 0.020 |
Why?
|
| Cytological Techniques | 1 | 2007 | 17 | 0.020 |
Why?
|
| Intraoperative Care | 1 | 2007 | 52 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2007 | 168 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2007 | 94 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2007 | 324 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 556 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2007 | 461 | 0.010 |
Why?
|
| Mitosis | 1 | 2005 | 17 | 0.010 |
Why?
|
| S100 Proteins | 1 | 2005 | 20 | 0.010 |
Why?
|
| Neuroblastoma | 1 | 2005 | 32 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2005 | 183 | 0.010 |
Why?
|
| Survival Rate | 1 | 2007 | 893 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2005 | 299 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2005 | 477 | 0.010 |
Why?
|
| Triamcinolone | 1 | 2003 | 12 | 0.010 |
Why?
|
| Apoptosis | 1 | 2005 | 375 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 729 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2005 | 461 | 0.010 |
Why?
|
| Administration, Topical | 1 | 2003 | 142 | 0.010 |
Why?
|
| Aging | 1 | 2008 | 942 | 0.010 |
Why?
|
| Neurons | 1 | 2005 | 486 | 0.010 |
Why?
|
| Prognosis | 1 | 2005 | 1534 | 0.010 |
Why?
|
| Child | 1 | 2007 | 2434 | 0.010 |
Why?
|